Pular para o conteúdo principal
Ranking Invest

RVNC - Revance Therapeutics, Inc.

Segmento: HealthcareRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Análise Ranking Invest

Valuation estimado
-$ 1.27 Bi
Último Balanço Atualizado: 3T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 163.03 Mi

Dívida Líquida

$ 424.86 Mi

L4T

-$ 181.44 Mi

MM4T

-74.52%

Indicadores Básicos

ROE

111.29%

Índices de Previsibilidade

Receita Líquida

D0.12

Lucro

C0.27

Margem

D0.77

Índices de Tendência

Receita Líquida

A11.23

Lucro

C2.33

Margem

A10.50

Índices de Endividamento

DIV/PAT

-2.61

DIV/L4T

-2.34

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.